Giuseppe Biondi-Zoccai, Attilio Lauretti, Stefan Agewall, Emmanuel Andres, Riccardo A Audisio, Deepak L Bhatt, Giuseppe Citerio, Jonathan A Drezner, Alexander Eggermont, Cetin Erol, Karen D Ersche, Giorgio Ferriero, Gerd Heusch, Ciro Indolfi, Paul A Insel, Carl J Lavie, Carlo La Vecchia, Nicola Maffulli, Fabrizio Montecucco, David J Moliterno, Stanley Nattel, Peter O'Kane, Elena Oliaro, Antonio Pelliccia, Michael Picard, Paolo Pozzilli, Fabiana Quaglia, Renata L Riha, Rupa Sarkar, Pietro Scicchitano, Jean-Louis Teboul, Hendrik Tevaearai Stahel, Loren E Wold, George W Booz
{"title":"Perspectives on Artificial Intelligence in Medical Publishing: A Survey of Medical Journal Editors.","authors":"Giuseppe Biondi-Zoccai, Attilio Lauretti, Stefan Agewall, Emmanuel Andres, Riccardo A Audisio, Deepak L Bhatt, Giuseppe Citerio, Jonathan A Drezner, Alexander Eggermont, Cetin Erol, Karen D Ersche, Giorgio Ferriero, Gerd Heusch, Ciro Indolfi, Paul A Insel, Carl J Lavie, Carlo La Vecchia, Nicola Maffulli, Fabrizio Montecucco, David J Moliterno, Stanley Nattel, Peter O'Kane, Elena Oliaro, Antonio Pelliccia, Michael Picard, Paolo Pozzilli, Fabiana Quaglia, Renata L Riha, Rupa Sarkar, Pietro Scicchitano, Jean-Louis Teboul, Hendrik Tevaearai Stahel, Loren E Wold, George W Booz","doi":"10.1097/FJC.0000000000001738","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Artificial intelligence (AI) has been increasingly integrated into medical publishing, hopefully improving efficiency and accuracy, but serious concerns persist regarding ethical implications, authorship attribution, and content reliability. We aimed at understanding the perspectives of editors of medical journals on AI. A structured online questionnaire was developed and distributed to editors-in-chief of medical journals worldwide. The survey comprised 27 concise questions exploring demographics, journal practices, and perspectives on AI in editorial workflows. Quantitative data were analyzed using descriptive statistics to summarize usage patterns, perceived benefits, risks, and future expectations. A total of 59 editors-in-chief completed the survey (response rate: 19%), with replies suggesting substantial variability in beliefs and attitudes toward AI for publication in medical journals. Artificial intelligence tools were already in use by 49% of journals, mainly for plagiarism detection (76%) and data verification (35%). Only 9% of responders reported that journals used AI for both scientific and linguistic review. Time savings (79%) and cost reduction (43%) were the most commonly cited benefits, and concerns included potential bias (71%) and lack of accountability (60%). Overall, 81% of responders anticipated a major role for AI in publishing within 10 years. Exploratory analyses suggested several potential associations between replies and respondent or journal features, requiring further validation in future surveys. In conclusion, this survey on attitudes toward AI in publication in medical journals suggests that editors-in-chief are cautiously adopting AI in their editorial workflow, supporting its operational use while explicitly calling for clear guidance to address ethical and regulatory concerns.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"374-383"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499947/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001738","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: Artificial intelligence (AI) has been increasingly integrated into medical publishing, hopefully improving efficiency and accuracy, but serious concerns persist regarding ethical implications, authorship attribution, and content reliability. We aimed at understanding the perspectives of editors of medical journals on AI. A structured online questionnaire was developed and distributed to editors-in-chief of medical journals worldwide. The survey comprised 27 concise questions exploring demographics, journal practices, and perspectives on AI in editorial workflows. Quantitative data were analyzed using descriptive statistics to summarize usage patterns, perceived benefits, risks, and future expectations. A total of 59 editors-in-chief completed the survey (response rate: 19%), with replies suggesting substantial variability in beliefs and attitudes toward AI for publication in medical journals. Artificial intelligence tools were already in use by 49% of journals, mainly for plagiarism detection (76%) and data verification (35%). Only 9% of responders reported that journals used AI for both scientific and linguistic review. Time savings (79%) and cost reduction (43%) were the most commonly cited benefits, and concerns included potential bias (71%) and lack of accountability (60%). Overall, 81% of responders anticipated a major role for AI in publishing within 10 years. Exploratory analyses suggested several potential associations between replies and respondent or journal features, requiring further validation in future surveys. In conclusion, this survey on attitudes toward AI in publication in medical journals suggests that editors-in-chief are cautiously adopting AI in their editorial workflow, supporting its operational use while explicitly calling for clear guidance to address ethical and regulatory concerns.
期刊介绍:
Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias.
Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.